Abingworth Management

About The Fund

Abingworth Management is an investment firm established in 1973, situated in London with additional offices in Menlo Park and Boston. They specialize in the life sciences and healthcare sectors with a focus on the United States and Europe-based companies. Their investment realm includes healthcare, life sciences, medical devices and hospital services, diagnostics, pharmaceutical sectors, and nucleic acid therapeutics. Abingworth believes in working with entrepreneurs to transform breakthrough science into medicine, providing time, patience, determination, experience, and capital. They support the creation of new treatments for patients, aiding biopharma companies in turning scientific discoveries into therapeutic realities. Abingworth's experience dates back to its first investment in a biotech startup in 1987, and it has since funded over a hundred companies. With a hands-on approach, they share their extensive knowledge gained from various scenarios in the life science sector. Innovation is central not only to their portfolio companies but also within Abingworth itself, as they've developed unique investment strategies such as VIPEs (Venture Investments in Public Equities) and Clinical Co-Development. With transatlantic access through their strategic locations, they provide a bridge between major biotech hubs, enhancing accessibility to new developments for entrepreneurs. Abingworth's portfolio ranges from early and seed stage to later stage, growth, expansion, PIPE, and buyout investments, with a minimum and maximum fund investment size of $30,950,000. Their specialized strategies enable them to support the next generation of biopharma enterprises and play a pivotal role in advancing the field of life science.